Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress - Eli Lilly and Company

1 sources2 storiesFirst seen 8/5/2026Score48Mixed Progress

Single Source

Bigness

Coverage

Recency

Engagement

Velocity

100

Confidence

Clipability

Polarization

Claims

Contradictions

Breakthrough

Sentiment Mix

Positive100%

Neutral0%

Negative0%

Geography

Europe

Expert Signals

Politics - Google News US Headlines

source • 2 mentions

AI-Generated Claims

Generated from linked receipts; click sources for full context.

Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand - WSJ.

Supported by 1 story

Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand WSJEli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Supported by 1 story

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress - Eli Lilly and Company.

Supported by 1 story

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress Eli Lilly and CompanyHere's How Much Traders See Eli Lilly Stock Moving After Earnings InvestopediaEli Lilly Q2 2026 earnings beat, raises full-year revenue forecast qz.comLilly Boosts Sales Guidance on Strong Demand for Obesity Drugs Bloomberg.comLilly's revenue soars 48%, driven by demand of its GLP-1s marketwatch.com

Supported by 1 story